Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trialsGregory J. Dore, Thomas Podsadecki, Brygida Knysz et al.|Journal of Hepatology|2015Cited by 68